desacetyl cephapirin has been researched along with Obesity in 1 studies
*Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY). [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alcaro, S; Ambrosio, FA; Artese, A; Bagetta, D; Carta, F; Catalano, R; Costa, G; Lupia, A; Maruca, A; Moraca, F; Ortuso, F; Rocca, R; Romeo, I; Supuran, CT; Vullo, D | 1 |
1 other study(ies) available for desacetyl cephapirin and Obesity
| Article | Year |
|---|---|
A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors.
Topics: Anti-Obesity Agents; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Computer-Aided Design; Drug Discovery; Drug Repositioning; Humans; Molecular Docking Simulation; Obesity | 2019 |